Health Canada Advances Modernization of Drug and Medical Device Review: Ministerial Trust Order and Generic Priority Review Consultation

Health Canada Advances Modernization of Drug and Medical Device Review

Date: July 15, 2026

Source: Health Canada

Core Content

Canadians expect timely access to safe and effective drugs and medical devices. Health Canada is taking concrete steps to modernize and improve the efficiency of its regulatory processes while maintaining high standards for safety, efficacy and quality.

July 15, 2026 | Ottawa, Ontario | Health Canada

Canadians expect timely access to safe and effective drugs and medical devices. Health Canada is taking concrete steps to modernize and improve the efficiency of its regulatory processes while maintaining high standards for safety, efficacy and quality.

Over the past three months, Health Canada authorized 537 new drugs and medical devices to help Canadians manage and treat a range of health conditions. This includes the first generic semaglutide products (three generic semaglutide products); Canada is the first G7 country to do so.

In addition, to help bring more drugs and treatments to Canada faster, Health Canada has issued the Ministerial Trust Order. The Order allows the Department to review certain parts of drug applications more quickly by using decisions or documents issued by selected foreign regulatory authorities. This approach reduces unnecessary duplication while maintaining Canada's requirements for safety, efficacy and quality. A more efficient process will also encourage manufacturers to bring products to Canada. Under the Order, the first drug categories accepted by Health Canada include pediatric drugs and veterinary drugs.

At the same time, Health Canada is seeking comments on a proposed approach to prioritize the review of certain generic drug applications involving Canadian manufacturing. Supporting Canada's generic drug and life sciences sectors will play a key role in strengthening drug supply security and preventing disruptive shortages that could negatively affect the health of Canadians.

Complementing Health Canada's regulatory modernization efforts, the Canadian Institutes of Health Research (CIHR) continues to support health research and clinical trials that generate the evidence needed to evaluate new drugs, medical devices and other health products. This helps strengthen Canada's life sciences ecosystem and improve Canadians' access to innovative treatments.

These initiatives are helping to build a more modern and efficient regulatory system—one that supports faster and broader access to medicines for Canadians without compromising Canada's high standards for safety, efficacy and quality.

Quotes

“Canadians expect timely access to safe and effective drugs and medical devices, without unnecessary delays. Health Canada is modernizing how marketing authorizations are reviewed and reducing duplication. These measures will help Canadians access safe and effective drugs and treatments when they need them.” — The Honourable Marjorie Michel, Minister of Health

“The Ministerial Trust Order is an important step in modernizing Canada's drug approval process, reducing regulatory duplication and accelerating access to necessary treatments. This is particularly important in pediatrics, where small patient populations and limited commercial incentives often delay the development and approval of therapies specifically for children.” — Emily Gruenwoldt, President and CEO of Children's Healthcare Canada and Executive Director of the Canadian Paediatric Chairs Association

“In the current trade environment, Canada's attractiveness as a market destination is under increasing pressure, making timely and effective implementation of the trust order particularly important. Its implementation represents an important opportunity to strengthen regulatory collaboration and alignment with international peers.” — Bettina Hamelin, PhD, President and CEO of Innovative Medicines Canada

Quick Facts

• Health Canada is seeking stakeholder comments on draft guidance describing the regulatory requirements of the Ministerial Trust Order and the process for submitting applications for review using this tool. The consultation is open from July 15, 2026 to September 12, 2026.
• In addition, the consultation on Health Canada's proposed approach to prioritize the review of certain generic drug applications involving domestic manufacturing is also open from July 15, 2026 to September 12, 2026.

Related product: Backgrounder—Drugs and medical devices authorized from April 1 to June 30, 2026.

Contacts: Alexandre Bergeron, Press Secretary, Office of the Minister of Health, alexandre.bergeron@hc-sc.gc.ca; Media Relations, Health Canada, 613-957-2983, media@hc-sc.gc.ca; Public enquiries: 613-957-2991, 1-866-225-0709.

Page details: July 16, 2026.

Source note: This article is based on public information from Health Canada: https://www.canada.ca/en/health-canada/news/2026/07/helping-canadians-access-safe-effective-treatments-and-medicines-faster.html. Specific requirements are subject to the latest official release by the regulator.

AIMEILI Regulatory Interpretation

This update is a regulatory policy and modernization announcement, not a product-specific approval, recall or safety notice. For medical device companies, the key is to determine whether it affects the registration pathway, technical documentation, labeling, quality management or post-market obligations. Although the Ministerial Trust Order currently focuses on certain drug categories—pediatric drugs and veterinary drugs—the broader modernization direction is relevant to companies planning or maintaining Canada market access.

Key Regulatory Signals

• Reliance on foreign decisions: The Ministerial Trust Order allows Health Canada to use decisions or documents from selected foreign regulators to expedite certain parts of drug reviews. The current first tranche covers pediatric and veterinary drugs; it does not yet establish a medical device reliance pathway. Companies should monitor whether and how the scope is expanded.
• Priority review linked to Canadian manufacturing: The proposed approach would prioritize certain generic drug applications involving Canadian manufacturing. This signals policy support for domestic manufacturing and supply security. For devices, there is no equivalent priority pathway in this announcement, but local manufacturing or Canadian partnerships may become more relevant in future policy design.
• Standards remain: Health Canada states that safety, efficacy and quality standards remain in place. Reliance or priority review does not remove the need for adequate technical evidence, quality system compliance and post-market obligations.

What Companies Should Check

Companies should first assess whether the update affects similar products, technologies or risk profiles in their portfolios. Priority checks include:

• Intended use and classification basis for the Canadian market;
• ISO 13485 quality management system evidence and Canadian-specific requirements;
• Risk management file and performance verification data;
• Clinical evaluation or clinical evidence;
• Labels and instructions for use, including English and French requirements;
• Authorization documents, Canadian authorized representative arrangements and existing registration certificates;
• Post-market surveillance, incident reporting and recall readiness.

Common Risks

• Unclear classification or regulatory pathway assumptions;
• Incomplete evidence chains between technical files, clinical evaluation and labeling claims;
• Labels and instructions for use not localized for Canada's English and French requirements;
• Unclear responsibilities of the Canadian authorized representative;
• Insufficient post-market maintenance planning for the Canadian market.

Business Impact for Medical Device Manufacturers

For Chinese medical device manufacturers planning to enter Canada, this announcement does not create an immediate new device approval shortcut. However, it reinforces the need to build Canada into international registration planning at an early stage. If Health Canada later extends reliance mechanisms to medical devices, products with prior FDA, EMA or MHRA approvals may be better positioned for faster Canadian review. Companies should nevertheless ensure that technical files, clinical evaluations and labeling meet Canadian requirements, including bilingual labeling and Canadian-specific standards.

For companies with Canadian manufacturing or local partners, the policy direction toward domestic manufacturing and supply security should be monitored for future opportunities. For companies relying solely on overseas manufacturing, the immediate impact is limited, but longer review timelines and local representation requirements should be factored into market access planning.

Overall, Canada's review modernization may offer faster market access opportunities, but it does not lower regulatory standards. Medical device companies should track the scope of the Ministerial Trust Order and any future extension to devices, assess product applicability, and prepare complete Canadian-specific documentation. Where appropriate, companies should work with regulatory advisors to develop a differentiated registration strategy and use the policy window effectively.

FAQ

Can the July 15, 2026 Health Canada announcement be used directly as a basis for submission? No. This article is for preliminary understanding and project assessment. Formal submissions must be based on the latest requirements of the target country's regulator, the product classification conclusion and the company's actual documentation.

What should companies do first after seeing this update? Conduct a documentation gap assessment to confirm whether the update affects the registration pathway, technical file, labeling, quality management system or post-market maintenance.

Applicability boundary: This article is for preliminary understanding, document preparation and project planning. It does not replace the official requirements of the target country's regulator, testing conclusions or legal advice.